You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普生物-B(02157.HK)擬配股總籌4.71億港元 加速核心產品商業化及研發
格隆匯 07-04 08:17

格隆匯7月4日丨樂普生物-B(02157.HK)發佈公吿,2025年7月4日(於交易時段前),公司(作為發行人)與配售代理(即中信證券及匯豐)訂立配售協議,據此,公司有條件同意發行,而配售代理有條件同意按單獨(而非共同或共同及單獨)基準,作為公司代理盡力促使以配售價每股H股5.02港元配售最多合共9382.5萬股配售股份。

配售股份(i)分別佔公司於本公吿日期全部現有已發行H股及全部現有已發行股本約5.66%及5.48%,且(ii)分別佔經根據配售事項發行配售股份擴大後的全部已發行H股及全部已發行股本約5.36%及5.20%。配售股份將根據一般授權予以配發及發行。

假設所有配售股份獲悉數配售,預計配售事項所得款項總額將約為4.71億港元,而配售事項所得款項總淨額預計將約為4.63億港元。公司擬將配售事項所得款項淨額(i)約20%(即9259萬港元)用於投資本公司核心產品MRG003(EGFR-ADC)的商業化及市場推廣;(ii)約60%(即2.78億港元)用於公司核心產品的臨牀試驗推進;及(iii)約20%(即9259萬港元)用於新產品管線的研發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account